$5 billion in Series C, co-led by Greenoaks and Sequoia

Isomorphic Labs, a U.K. company that designs and develops new medicines with AI, said on Nov. 17 (Nov. 17 Japan time) that it has raised $5 billion in Series C funding. Investment firm Greenoaks and Sequoia Capital co-led the round, joined by Andreessen Horowitz (a16z) and "several other new investors." The round was oversubscribed, the company said.

Alphabet again invested a large amount ("continued significant investment"). All existing investors, Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K.'s UK Sovereign AI Fund, also took part. The release does not give the valuation, the amount from each investor or Alphabet's stake.

Founder and CEO Demis Hassabis announced the funding on X at 9:06 p.m. Nov. 17 Japan time. He said the money will accelerate the company's mission to "Solve All Disease."

Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...

Series B in May was $2.1 billion; the new round is more than twice as large, six months later

The company announced on May 12 that it had raised $2.1 billion in Series B funding. That round was led by Thrive Capital, with existing backers Alphabet and GV joined by new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The $5 billion raised now is more than twice that amount, about six months later. The four investors that joined in the Series B took part this time as "existing investors," while Greenoaks, Sequoia Capital, a16z and others joined as new investors.

Isomorphic Labs funding rounds, according to the company's announcementsAmount ($ billion)
2.1
May 12, 2026Series B
5
Nov. 17, 2026Series C

Funds go to the IsoDDE drug design engine and preparation for clinical trials

According to the release, the company is scaling its proprietary drug design engine "IsoDDE" and its pipeline of therapeutic candidates designed with AI. It described IsoDDE as unifying a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities. The engine explores vast chemical spaces and is used to design and refine molecules with drug-like properties, the company said. It uses the models together with its own AI agents that navigate and reason over complex biological systems.

With the new money, the company will further mature IsoDDE and expand into new areas of biology with advanced models. It will build a partner ecosystem to advance the understanding of how diseases work. The funds will also go toward building global infrastructure for AI-led bioengineering and the development capabilities needed to move drug candidates into clinical trials. The company did not say how the money will be split among these uses.

Positive preclinical results; clinical trials still ahead

The release said positive preclinical results, meaning results from before human testing, have come from both internal programs in oncology and immunology and programs with partners. It said this is "setting the stage for clinical entry." Hassabis said the company will drive its first therapeutic programs toward clinical trials.

However, the release does not give a start date for clinical trials, the names of drug candidates or figures from the preclinical results. It also does not say which partner programs are involved.

Investors cite prediction accuracy

President Max Jaderberg said, "Every week we are making repeatable scientific advancements enabled by our models." Neil Mehta, founder of Greenoaks, said the company is building deep learning systems that can predict complex biological behavior with high accuracy. Konstantine Buhler, a partner at Sequoia Capital, said the company is turning advanced AI into a growing portfolio of drug candidates.

Isomorphic Labs was founded in 2021 and is headquartered in London. It also has offices in Cambridge, Massachusetts, and Lausanne, Switzerland, and is pursuing drug discovery through both partnered and wholly owned programs.

Other major AI companies are also moving into AI drug discovery. Anthropic said on Oct. 28 that it had partnered with six companies on drug development and was starting its own drug discovery. OpenAI announced in October that it was acquiring Orchestra Bio, which manages drug development operations.